Aging
Navigate
Submit an Article
Research Perspective|Volume 1, Issue 11|pp 949—953

Paradoxical down-regulation of p16INK4a mRNA with advancing age in Acute Myeloid Leukemia

Hendrik J.M. de Jonge1, Carolien M. Woolthuis2, Eveline S.J.M. de Bont1, Gerwin Huls2
  • 1Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  • 2Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Received: October 1, 2009Accepted: October 21, 2009Published: October 23, 2009
https://doi.org/10.18632/aging.100096

Copyright: © 2009 de Jonge et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Aging is generally considered to be the consequence of stem cell attrition caused by the activity of tumor suppressor pathways that censor potentially malignant clones by eliciting apoptosis or senescence. An important effector of aging is the cyclindependent kinase inhibitor p16INK4a, which is also a known suppressor of cancer. The expression of p16INK4a is very low or absent in young organisms but increases with advancing age. We recently showed that, unlike healthy cells, acute myeloid leukemia (AML) derived blasts show a down-regulation of p16INK4a mRNA with increasing age. Based on this observation we hypothesize that suppression of defense mechanisms which protect older cells against cellular and DNA damage might facilitate oncogenesis in older individuals.